Remicade Safety Line (Crohn's Disease)(Study P03288)(COMPLETED)

Merck Sharp & Dohme (MSD)

Status: Completed

Conditions: Crohn's Disease

Treatments: Biological: Remicade (infliximab)

Study type: Observational

Funder types: Industry

Identifiers

NCT00818272

P03288

Details and patient eligibility

About

This observational study is in line with the German educational plan with the aim to implement a tool to increase and monitor the awareness for tuberculosis screening and to reinforce the patient eligibility for a treatment with Remicade according to the Summary of Product Characteristics (SmPc).

Enrollment: 148 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects with Crohn's disease.

Exclusion criteria

• As per SmPC

Trial design

148 participants in 1 patient group

Remicade (infliximab)

Description:

Participants with confirmed diagnosis of active Crohn's disease.

Treatment:

Biological: Remicade (infliximab)